GlassScriptPhysician profile
Pranay Janardan Bhatt
NPI 1952381287
$16,044.58
in general payments reported to CMS, 2019-2025
56 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $1,248 · 2021: $2,397 · 2022: $2,380 · 2023: $3,008 · 2024: $2,805 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,833.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,703.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,604.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,288.74 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,268.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,103.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $826.16 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $532.18 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $500.13 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $445.48 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Abbvie INC. | $378.69 | 2021-2025 | Qulipta, Vraylar, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.21 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $356.24 | 2019-2025 | |
| Amgen INC. | $320.74 | 2019-2025 | Otezla, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $314.05 | 2019-2024 | Eliquis |
| Amarin Pharma, INC. | $313.17 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranay Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.